Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More…
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Phone650-251-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$787.31 million
Profitability
Miscellaneous
Employees2,480
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Thursday, July, 25th. The company reported $0.51 EPS for the quarter, topping the Zacks' consensus estimate of $0.47 by $0.04. The company earned $217.40 million during the quarter, compared to the consensus estimate of $214.13 million. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. The company's quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.46 EPS. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
How can I listen to Omnicell's earnings call?
Omnicell will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Omnicell issued on next quarter's earnings?
Omnicell issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share guidance of $2.65-$2.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.77. The company issued revenue guidance of $886-$900 million, compared to the consensus revenue estimate of $891.96 million.
What price target have analysts set for OMCL?
7 brokers have issued 12 month target prices for Omnicell's stock. Their forecasts range from $61.00 to $90.00. On average, they anticipate Omnicell's stock price to reach $80.29 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
Has Omnicell been receiving favorable news coverage?
Headlines about OMCL stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Omnicell earned a news impact score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Omnicell.
Who are some of Omnicell's key competitors?
What other stocks do shareholders of Omnicell own?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
- Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by a number of of institutional and retail investors. Top institutional investors include Stephens Investment Management Group LLC (0.80%), Tributary Capital Management LLC (0.65%), Peregrine Capital Management LLC (0.65%), Summit Creek Advisors LLC (0.53%), Scout Investments Inc. (0.44%) and Rhenman & Partners Asset Management AB (0.22%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.
Which major investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Pwmco LLC, Scout Investments Inc., Rhenman & Partners Asset Management AB, Tributary Capital Management LLC, Stephens Investment Management Group LLC, CIBC Private Wealth Group LLC and Envestnet Asset Management Inc.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.
Which major investors are buying Omnicell stock?
OMCL stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Summit Creek Advisors LLC, Bowling Portfolio Management LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Zurcher Kantonalbank Zurich Cantonalbank , Stephens Inc. AR and West Coast Financial LLC. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $76.07.
How big of a company is Omnicell?
Omnicell has a market capitalization of $3.17 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
